

Journal Pre-proof

Non-irritant concentrations for skin testing with SARS-CoV-2 mRNA Vaccine

João Marcelino, MD, Sofia Farinha, MD, Rita Silva, MD, Irina Didenko, MD, Miguel Proença, MD, Elza Tomás, MD



PII: S2213-2198(21)00329-9

DOI: <https://doi.org/10.1016/j.jaip.2021.03.022>

Reference: JAIP 3510

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*

Received Date: 5 January 2021

Revised Date: 27 February 2021

Accepted Date: 10 March 2021

Please cite this article as: Marcelino J, Farinha S, Silva R, Didenko I, Proença M, Tomás E, Non-irritant concentrations for skin testing with SARS-CoV-2 mRNA Vaccine, *The Journal of Allergy and Clinical Immunology: In Practice* (2021), doi: <https://doi.org/10.1016/j.jaip.2021.03.022>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

Title:**Non-irritant concentrations for skin testing with SARS-CoV-2 mRNA Vaccine****Running title:**

Non-irritant concentrations for CoV-2 Vaccine

Authors:

João Marcelino MD¹, Sofia Farinha MD¹, Rita Silva MD¹, Irina Didenko MD¹, Miguel Proença MD¹, Elza Tomás MD¹

1 - Immunoallergology Department, Centro Hospitalar de Setúbal EPE, Setúbal, Portugal

Corresponding author contact information:

Name: João Luís Alves Marcelino M.D

Hospital de Santa Maria CHLN EPE

Immunoallergology

Avenida Professor Egas Moniz

Lisbon, 1649-035

PORTUGAL

E-mail: jlam_1987@sapo.pt

Phone: +351 967872677

Previous presentation: This never has never been presented.

Conflict of interests: The authors declare no conflict of interest.

Funding: Intramural

Word count: 715/1000

Tables/figures: 1/2

Clinical Implications

Skin testing (prick test and intradermal test) can be performed with the Pfizer–BioNtech SARS-CoV-2 vaccine, up to the undiluted form, without the risk of eliciting an immediate irritant reaction. This finding can help the evaluation of patients with an immediate reaction to the first dose of the vaccine or with a suspected immediate reaction to a component of the vaccine and who require vaccination due to the coronavirus pandemic.

36

37

38 The importance of vaccination to the coronavirus disease 2019 (COVID-19) pandemic cannot be
39 understated. However, reports of anaphylaxis associated with the Pfizer SARS-CoV-2 vaccine are emerging
40 with the beginning of large-scale vaccination. (1) Preliminary data suggests an incidence of anaphylaxis of
41 approximately 1 in 100,000 injections, 10 times greater than the incidence of traditional vaccines.
42 Hypersensitivity to the vaccine, or to one of its components, has generally been established as a
43 contraindication to the vaccine administration. (1)

44 Concerning the observed anaphylactic reactions, the pathophysiology remains to be determined.
45 An IgE-mediated pathway must be considered. Polyethylene glycol (PEG) 2000, used as a stabilizer of the
46 lipid-based nanoparticle carrier system of Pfizer SARS-CoV-2 vaccine, has been pointed as a possible culprit,
47 and its role in inducing IgE-mediated anaphylaxis is well documented (1, 2). Therefore, skin testing with the
48 vaccine may prove a valuable method to evaluate patients who experienced immediate reactions with the
49 first dose of the vaccine, as well as to identify people with allergy to the vaccine or its components and who
50 should avoid it. The biggest problems in using the vaccine is the lack of information concerning the
51 adequate (non- irritant) concentration for the skin tests, (3) and the need for additional vaccine to perform
52 the tests, especially considering the need for a quick worldwide vaccination and the consequent scarcity of
53 the vaccine.

54 Pfizer's specifications regarding the vaccine use states that each vial contains enough for 5 doses
55 with a six-hour viability before inoculation. In some settings, healthcare professionals have used the surplus
56 in each vial for an additional 6th dose. Even in these cases, each vial still contains a small quantity of
57 vaccine, which can be used to perform skin tests.

58 Taking advantage of this fact, we evaluated 55 healthcare professionals to determine non-irritant
59 concentrations for skin testing with SARS-CoV-2 mRNA Vaccine.

60 All participants were selected from a group of healthcare professionals being vaccinated with the
61 Pfizer SARS-CoV-2 vaccine, as part of the Portuguese National Vaccination Plan. Participants were
62 inoculated with the first dose of the vaccine, and if they remained asymptomatic for 30 minutes, they were
63 considered eligible for skin testing. Participants were excluded if they took anti-histamines or drugs with
64 anti-histamine properties in the 5 previous days. All participants signed an informed consent. Patients were
65 questioned on their atopic history and, specifically, drug allergy. Additional information from their clinical
66 files was added retrospectively.

67 Each person underwent skin prick and intradermal tests with the undiluted vaccine and with a
68 dilution of 1/10 with saline. The tests were performed in accordance with the literature. (4) A positive
69 control with histamine (10mg/mL) and a negative control with saline, performed by prick test, were also
70 carried out. Readings were made after 15 and 30 minutes for every test.

Seventy-five percent of the patients were women, with an average age of 42 ± 12 years (between 23 and 67 years of age). Atopic history is detailed in table 1. None of the patients had a history suggestive of polyethylenoglycol (PEG) allergy, or allergy to other vaccines. Three of the participants presented a history of anaphylaxis: one selective to indomethacin (with no previous evaluation by an allergologist, but with a very suggestive story), another to Pru p 3 (previously confirmed by an allergologist), and the last had IgE-mediated allergy to penicillin and NSAID-induced asthma and urticaria (previously confirmed by an allergologist).

All the skin prick tests with histamine were positive (wheals between 4x4 mm and 9x8 mm). All negative control prick tests were negative with the exception of a patient with symptomatic dermatographism (wheal of 5x5 mm).

In 53 patients (96%), the vaccine prick and intradermal tests were negative. One patient showed erythema without pruritus or increase in diameter of the intradermal wheal in both the undiluted and 1/10 dilution. Another participant, with symptomatic dermatographism, showed a positive reaction to the skin prick and intradermal tests, including the skin prick test with saline.

No participant developed symptoms suggestive of an allergic reaction within 24 hours of the first inoculation.

In conclusion, skin prick testing and intradermal testing can be done with the Pfizer–BioNtech SARS-CoV-2 vaccine with its undiluted form. An open question remains about the exact positive predictive value these tests may have. These findings cannot be generalized to other vaccine preparations and do not address delayed reactions or adverse effects.

Table 1 – Atopic history of the participants. *1 case of anaphylaxis related to Pru p 3, and 1 case of oral allergy syndrome related to nuts. ** Urticaria with beta-lactam antibiotics, with positive skin tests and/or oral provocation tests and NSAID-induced asthma and urticaria. *** 2 cases of urticarial-like symptoms with amoxicillin, 1 case of urticarial-like symptoms with metoclopramide, 1 case of urticarial-like symptoms with oral acetylcysteine, 1 case of face angioedema with aspirin (tolerating other NSAIDs), and 1 case of anaphylaxis with indomethacin (consistent history on 2 separate occasions, tolerating other NSAIDs).

Atopic history	Number of patients (n=55)
Allergic rhinitis confirmed by allergic testing	11
Non-allergic rhinitis confirmed by allergic testing	1
Rhinitis-like symptoms with no previous evaluation by allergology	6
Allergic asthma confirmed by allergic testing	10
Non-allergic asthma confirmed by allergic testing	1
Asthma-like symptoms with no previous evaluation by allergology	2
Food allergy confirmed by allergic testing	2*
Food allergy with no previous evaluation by allergology	0

Drug allergy confirmed by allergic testing	1**
Drug allergy with no previous evaluation by allergology	6***

99

100

101

REFERENCES:

102

1 - Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2020 Dec 30

103

2 - Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin

104

Exp Allergy. 2016 Jul;46(7):907-22

105

3 - Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test

106

concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position

107

paper. Allergy. 2013 Jun;68(6):702-12

108

4 - Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin

109

test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002 Jan;57(1):45-51